Opportunity for Substantial Loss Investors of Applied Therapeutics to Join Class Action Lawsuit

Class Action Lawsuit Against Applied Therapeutics, Inc.

On December 29, 2024, Bronstein, Gewirtz & Grossman, LLC, a prominent law firm recognized nationwide, issued a notification to investors of Applied Therapeutics, Inc. (NASDAQ: APLT) about an ongoing class action lawsuit. This action is significant for anyone who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024.

What Is the Class Action About?

The class action lawsuit alleges that throughout the specified period, executives at Applied Therapeutics misled investors with false statements and omissions regarding the company's New Drug Application (NDA) for their experimental drug, govorestat. Critics state that the NDA contained significant deficiencies making it unlikely for the FDA to approve it and that the clinical data provided did not adequately demonstrate the drug’s safety or effectiveness. Furthermore, the lawsuit claims that earlier positive assertions made by the company about the likelihood of receiving FDA approval for govorestat were misleading and lacked a reasonable basis.

This action brings to light the serious consequences of inadequate transparency in corporate communications, especially in the healthcare sector, where investor trust is paramount. With rising scrutiny from various regulatory bodies, it’s crucial for companies to uphold a high standard of truthfulness in their disclosures.

How to Participate

Investors who believe they suffered considerable losses from investments in Applied Therapeutics during the designated period are urged to consider participating in the class action. Individuals can learn more about this opportunity by visiting bgandg.com/APLT. The deadline to apply for appointment as lead plaintiff in this lawsuit is February 18, 2025.

No Financial Risk to Participants

Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, which means that investors will not be financially liable unless the case results in a successful recovery. This structure ensures that even those who may be hesitant to engage in legal action due to financial concerns can still seek justice and potential compensation.

The Reputation of Bronstein, Gewirtz & Grossman, LLC

This law firm has a well-established track record in managing securities fraud class actions and shareholder derivative suits, having successfully recovered hundreds of millions of dollars for investors nationwide. With a commitment to advocating for shareholder rights, they have garnered a reputation for their thorough and determined approach.

Keep Updated

For ongoing updates, individuals can follow Bronstein, Gewirtz & Grossman, LLC on platforms such as LinkedIn, X, Facebook, or Instagram. It is essential for investors to stay informed about the latest developments regarding their rights and potential actions they can take to recover losses.

In conclusion, if you have invested in Applied Therapeutics and felt any impact from the potential mismanagement or misleading statements during the specified timeframe, don’t hesitate to take action. This class action may provide a viable avenue for recourse and recovery.